Business

Follow the Science: Bridging the Biosimilar Gap With Dr Hillel Cohen

July 27th 2025

By Skylar Jeremias

Explore the evolving biosimilars landscape with expert insights on development, regulation, and global health harmonization in this engaging podcast episode.

Medicare Price Negotiations Will Slow Biosimilar Momentum, Widening Market Gap

July 16th 2025

By Skylar Jeremias

Government price negotiations under the Inflation Reduction Act may hinder biosimilar development, impacting drug costs and patient access to affordable therapies.

White Paper Offers Tips for Sustaining Biosimilar Progress, Avoiding a Market Void

July 15th 2025

By Skylar Jeremias

Biosimilars face a potential void as biologics lose exclusivity, prompting urgent calls for policy reform and enhanced education to ensure market sustainability.

Eye on Pharma: Keytruda Biosimilar Deal; German Court Bans Imraldi; New Biosimilars for Japan

June 17th 2025

By Skylar Jeremias

Alvotech and Dr. Reddy's partner to develop a Keytruda biosimilar, a German court bans Humira biosimilar over patent dispute, and Samsung Bioepis enters a strategic agreement with NIPRO Corporation in Japan.

Sandoz, STADA, and Samsung Bioepis Report Strong Earnings From Biosimilars

June 10th 2025

By Skylar Jeremias

Leading biosimilar companies Sandoz, STADA Arzneimittel, and Samsung Bioepis report impressive Q1 2025 growth, driven by strong denosumab biosimilars and expanding portfolios.

Billions in Health Care Savings Realized Through Early Generic, Biosimilar Settlements

June 4th 2025

By Skylar Jeremias

Patent settlements accelerate the entry of generics and biosimilars, saving the health care system $422.9 billion and enhancing drug accessibility.

Wyost and Jubbonti Launch as First Denosumab Biosimilars in the US

June 2nd 2025

By Skylar Jeremias

Denosumab biosimilars Wyost and Jubbonti launch in the US, enhancing access to affordable treatments for osteoporosis and cancer-related skeletal events.

Eye on Pharma: Interchangeability Labels and Expanded Biosimilar Partnerships

May 29th 2025

By Skylar Jeremias

The FDA designates 2 biosimilars as interchangeable, enhancing access to treatments for inflammatory diseases and multiple sclerosis, while 2 other companies expand their biosimilar partnership to include more products.

The Trump Administration’s Drug Price Actions and Why US Prices Are Already Sky-High

May 17th 2025

By Skylar Jeremias

While the Trump administration’s latest executive order touts sweeping drug price cuts through international benchmarking, the broader pharmaceutical pricing crisis in the US reveals a far more complex web of development costs, profit incentives, and absent price controls—raising the question of whether any single policy, including potential drug tariffs, can truly untangle it.

Eye on Pharma: Interchangeability, Private Labels, and Patent Settlements for Biosimilars

May 9th 2025

By Skylar Jeremias